Massimo Massaia, MD, Santa Croce e Carle di Cuneo Hospital, Cuneo, Italy, briefly discusses the growing role of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL), highlighting its value as a clinical endpoint in patients receiving continuous and fixed-duration treatment. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.